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Abstract: Pseudomonas aeruginosa is an opportunistic human pathogen associated with cystic fibrosis.
This bacterium produces, among other virulence factors, a soluble d-galactose-specific lectin PA-IL
(LecA). PA-IL plays an important role in the adhesion to the host cells and is also cytotoxic. Therefore,
this protein is an interesting therapeutic target, suitable for inhibition by carbohydrate-based
compounds. In the current study, β-d-galactopyranoside-containing tri- and tetravalent glycoclusters
were synthesized. Methyl gallate and pentaerythritol equipped with propargyl groups were chosen
as multivalent scaffolds and the galactoclusters were built from the above-mentioned cores by
coupling ethylene or tetraethylene glycol-bridges and peracetylated propargyl β-d-galactosides
using 1,3-dipolar azide-alkyne cycloaddition. The interaction between galactoside derivatives and
PA-IL was investigated by several biophysical methods, including hemagglutination inhibition assay,
isothermal titration calorimetry, analytical ultracentrifugation, and surface plasmon resonance. Their
ability to inhibit the adhesion of P. aeruginosa to bronchial cells was determined by ex vivo assay.
The newly synthesized multivalent galactoclusters proved to be significantly better ligands than
simple d-galactose for lectin PA-IL and as a result, two representatives of the dendrimers were able
to decrease adhesion of P. aeruginosa to bronchial cells to approximately 32% and 42%, respectively.
The results may provide an opportunity to develop anti-adhesion therapy for the treatment of
P. aeruginosa infection.
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1. Introduction
Lectins are specific carbohydrate-binding proteins of a non-immune origin. Lectins from the
pathogens could be important virulence factors involved in recognition and adhesion processes
between pathogens and hosts [1]. Therefore, lectins are promising therapeutic targets which could be
inhibited by carbohydrate-based inhibitors [2]. Lectins are usually multivalent proteins, containing
several binding sites per molecule and/or forming oligomers. They frequently display an avidity
effect, resulting in significantly increased affinity towards glycosylated surfaces. Consequently,
the multivalent compounds with multiple carbohydrate moieties available are considered to be a
possible method to efficiently inhibit lectins [3].
The Gram-negative bacterium Pseudomonas aeruginosa is an important opportunistic pathogen
causing lung infections in immunocompromised individuals, especially cystic fibrosis patients. It is
the most common pathogen associated with this hereditary disease [4]. P. aeruginosa produces soluble
d-galactose-specific lectin PA-IL (LecA) [5,6]. PA-IL is a tetrameric calcium-dependent lectin with
one binding site per monomer. Each binding site contains one calcium ion directly involved in
the carbohydrate recognition and binding [7]. PA-IL is considered to be a significant virulence
factor [8]. In addition to its supposed primary role as an adhesin, the lectin is involved in the biofilm
formation [9] and is cytotoxic. Specifically, PA-IL displayed toxicity to respiratory epithelial cells in
primary culture [10]. Due to its importance, several types of multivalent inhibitors were designed and
tested against PA-IL, including fullerene-based glycoclusters [11], glycodendrimers [12], glycopeptide
dendrimers [13], resorcin[4]arene-based glycoclusters [14], inhibitors based on porphyrin scaffold and
β-peptoids [15], glycosylated poly(phenylacetylene)s [16], glycoconjugates based on a calix[4]arene
scaffold [17,18] and on a pentaerythritol core [19]. Furthermore, the d-galactose surface-modified
polymeric nanoparticles [20] and glycodendrimer micelles [21] were prepared.
In many cases, the efficiency of multivalent carbohydrate-based inhibitors is based on the chelate
effect—the intramolecular binding of multivalent ligand to several binding sites of lectin. However,
the multivalent inhibitors can also cross-link lectin molecules by intermolecular binding, possibly
resulting in the formation of large aggregates and subsequent precipitation of the complexes [22].
Considering PA-IL, it was suggested that tetravalent inhibitors capable of lectin cross-linking are
the most suitable for the inhibition of Pseudomonas aeruginosa biofilm formation [23]. The ability of
multivalent compounds to cross-link lectins can also lead to cross-linking and aggregation of bacteria
cells presenting these lectins on their surfaces [18,24,25]. This aggregation can serve as proof that
inhibitors are able to interact with native lectins on the cells surfaces; however, it can also interfere
with biofilm formation. A negative correlation to biofilm formation was observed for the aggregation
of Pseudomonas aeruginosa cells [26].
In the current paper, we describe the efficient synthesis of β-d-galactopyranoside-presenting
oligovalent glycoclusters and their testing as inhibitors of the lectin PA-IL. Their inhibitory potency
was determined by hemagglutination inhibition assay and surface plasmon resonance. Interactions
were characterized using isothermal titration calorimetry and the cross-linking ability was examined
by analytical ultracentrifugation and experiments with whole Pseudomonas aeruginosa cells. Selected
compounds were further tested for their ability to inhibit the adhesion of P. aeruginosa to epithelial
bronchial cells derived from a cystic fibrosis patient in an ex vivo assay.
2. Materials and Methods
2.1. General Methods
Optical rotations were measured at room temperature with a Perkin-Elmer 241 automatic
polarimeter (PerkinElmer, Waltham, MA, USA). TLC analysis was performed on Kieselgel 60 F254 silica
gel plates (Merck, Kenilworth, NJ, USA) with visualization by immersing in a sulfuric-acid solution
(5% in EtOH, VWR International Ltd., Radnor, PA, USA) followed by heating. Column chromatography
was performed on silica gel 60 (Merck 0.063–0.200 mm) and flash column chromatography was
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performed on silica gel 60 (Merck 0.040–0.063 mm). Gel filtration was performed on Sephadex G-25
using methanol as the eluent. Organic solutions were dried over MgSO4 and concentrated under
vacuum. The 1H (400 and 500 MHz) and 13C NMR (100.28, 125.76 MHz) spectra were recorded with
Bruker DRX-400 and Bruker Avance II 500 spectrometers (Billerica, MA, USA). Chemical shifts are
referenced to Me4Si or DSS (0.00 ppm for 1H) and to solvent signals (CDCl3: 77.00 ppm, CD3OD:
49.15 ppm for 13C). MS (MALDI-TOF) analysis was carried out in positive reflectron mode with a
BIFLEX III mass spectrometer (Billerica, MA, USA) with delayed-ion extraction. The matrix solution
was a saturated solution of 2,4,6-trihydroxy-acetophenone (THAP) in CH3CN.
2.2. Synthesis
2.2.1. General Method A for Azide-Alkyne Click Reaction
Et3N (1 equiv./alkyne) and Cu(I)I (0.1 equiv./alkyne) were added to a stirred solution of alkyne
(1.5 equiv/azide moiety) and azide in CH3CN under an argon atmosphere and stirred overnight at
room temperature. The reaction mixture was evaporated and the crude product was purified by flash
column chromatography to give the desired compound.
2.2.2. General Method B for Zemplén-Deacetylation
A catalytic amount of NaOMe (pH = 9) was added to a stirred solution of ester (0.2 mmol) in dry
MeOH (5 mL) and stirred overnight at room temperature. The reaction mixture was neutralized with
Amberlite IR-120 H+ ion-exchange resin, filtered and evaporated, then the crude product was purified
by flash column chromatography and gel filtration to give the desired compound.
2.2.3. Compound 3
Azide compound 1 (100 mg, 0.10 mmol) and alkyne 2 (169 mg, 0.44 mmol) were reacted in CH3CN
according to the general method A. The crude product was purified by flash column chromatography
(95:5 CH2Cl2:MeOH) to give compound 3 (118 mg, 55%) as a colourless syrup. [α]24D –21.96 (c 0.46,
CHCl3); Rf 0.33 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3): δ = 7.94, 7.90, 7.72 (3 x s, 6H,
6 x CH triazole), 7.44 (s, 2H, arom), 5.40 (d, J = 2.9 Hz, 3H, skeleton proton), 5.23 (s, 6H, 3 x CH2),
5.20–5.18 (m, 3H, 3 x skeleton protons), 5.02 (dd, J = 3.4 Hz, J = 10.4 Hz, 3H, 3 x skeleton protons),
4.94 (d, J = 12.5 Hz, 3H, 3 x H-6a), 4.80 (d, J = 12.5 Hz, 3H, 3 x H-6b), 4.68 (d, J = 7.9 Hz, 3H, 3 x H-1),
4.59–4.50 (m, 11H, 3 x H-5, 4 x CH2), 4.18–4.15 (m, 6H, 3 x CH2), 3.99–3.84 (m, 19H, 8 x CH2, COOCH3),
3.61-3.55 (m, 24H, 12 x CH2), 2.15, 2.06, 1.97 (3 x s, 36H, 12 x CH3 acetyl) ppm; 13C NMR (100 MHz,
CDCl3) δ = 170.4, 170.2, 170.1, 169.5 (12C, 12 x CO acetyl), 166.3 (1C, COOCH3), 152.0 (2C, 2 x Cq arom),
144.0, 148.8, 143.1, 141.6 (6C, 6 x Cq triazole), 125.7 (2C, 2 x Cq arom), 124.9, 124.5, 124.0 (6C, 6 x CH
triazole), 109.2 (2C, arom), 100.3, 100.2 (3C, 3 x C-1), 70.9, 70.8, 68.8, 67.1 (12C, 3 x skeleton carbons),
70.5, 70.4, 69.3 (18C, 18 x CH2 TEG), 63.0, 62.8, 62.7 (3C, 3 x C-6), 61.3 (6C, 6 x CH2 propargyl), 52.4
(1C, COOCH3), 50.3, 50.2, 50.1 (6C, 6 x NCH2 TEG), 20.7, 20.6 (12C, 12 x CH3 acetyl) ppm; MALDI-TOF
(positive ion): m/z calcd for C92H128N18NaO44: 2211.82 [M + Na]+ Found: 2211.78.
2.2.4. Compound 4
Compound 3 (86 mg, 0.04 mmol) was deacetylated according to general method B. The crude
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 4 (48 mg,
73%) as a colourless syrup. [α]24D—6.4 (c 0.14, MeOH); Rf 0.34 (7:3 CH3CN:H2O); 1H NMR (400 MHz,
D2O): δ = 8.00, 7.92, 7.73 (3 x s, 6H, 6 x CH triazole), 7.29 (s, 2H, arom), 5.08 (s, 4H, 2 x CH2 propargyl),
5.01 (s, 2H, CH2 propargyl), 4.84-4.65 (m, 6H, 3 x CH2 propargyl), 4.51-4.38 (m, 12H, 6 x NCH2 TEG),
4.34 (d, J = 7.7 Hz, 3H, 3 x H-1), 3.81–3.70 (m, 22H, 3 x H-4, COOCH3, 8 x OCH2 TEG), 3.69-3.61
(m, 6H, 3 x H-6a,b), 3.56 (dd, J = 4.4 Hz, J = 7.5 Hz, 3H, 3 x H-5), 3.50 (dd, J = 3.4 Hz, J = 9.9 Hz, 3H,
3 x H-3), 3.44–3.32 (m, 23H, 3 x H-2, 10 x OCH2 TEG) ppm; 13C NMR (100 MHz, D2O) δ = 168.7 (1C,
COOCH3), 152.4 (2C, 2 x Cq arom), 144.6, 143.8, 141.3 (6C, 6 x Cq triazole), 126.7, 126.4 (6C, 6 x CH
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triazole), 126.5 (2C, 2 x Cq arom), 110.1 (2C, arom), 103.0 (3C, 3 x C-1), 76.2 (3C, 3 x C-5), 73.8 (3C,
3 x C-3), 71.6 (3C, 3 x C-2), 70.7, 70.6, 70.4, 70.0, 69.6 (18C, 18 x CH2 TEG), 69.5 (3C, 3 x C-4), 66.0, 62.9
61.7 (6C, 6 x CH2 propargyl), 61.9 (3C, 3 x C-6), 53.9 (1C, COOCH3), 51.1, 51.0, 50.9 (6C, 6 x NCH2 TEG)
ppm; MALDI-TOF (positive ion): m/z calcd for C68H104N18NaO32: 1707.70 [M + Na]+ Found: 1707.65.
2.2.5. Compound 6
Azide compound 5 (85 mg, 0.05 mmol) and alkyne 2 (111 mg, 0.29 mmol) were reacted in CH3CN
according to general method A. The crude product was purified by flash column chromatography (95:5
CH2Cl2:MeOH) to give compound 6 (79 mg, 42%) as a colourless syrup. [α]24D—16.9 (c 0.13, CHCl3);
Rf 0.38 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.73, 7.72 (2 x s, 8H, 8 x CH triazole),
5.40 (d, J = 2.8 Hz, 4H, 4 x H-4), 5.20 (dd, J = 8.0 Hz, J = 10.4 Hz, 4H, 4 x H-2), 5.02 (dd, J = 3.4 Hz,
J = 10.4 Hz, 4H, 4 x H-3), 4.95 (d, J = 12.5 Hz, 4H, 4 x CH2a), 4.80 (d, J = 12.5 Hz, 4H, 4 x CH2b), 4.68
(d, J = 8.0 Hz, 4H, 4 x H-1), 4.58–4.53 (m, 20H, 8 x CH2 propargyl, 2 x CH2 TEG), 4.19–4.15 (m, 8H,
4 x H-6a,b), 3.99-3.94 (m, 4H, 4 x H-5), 3.90-3.86 (m, 20H, 10 x CH2 TEG), 3.62-3.58 (m, 32H, 16 x CH2
TEG), 3.46 (s, 8H, 4 x CH2 pentaerythritol), 2.15, 2.06, 1.98, 1.97 (4 x s, 48H, 16 x CH3 acetyl) ppm; 13C
NMR (100 MHz, CDCl3) δ = 170.4, 170.2, 170.1, 169.5 (16C, 16 x CO acetyl), 145.0, 143.9 (8C, Cq triazole),
124.0, 123.7 (8C, CH triazole), 100.3 (4C, 4 x C-1), 70.9, 70.8, 68.8, 67.1 (16C, 4 x skeleton carbons), 70.5,
70.4, 69.4, 69.3, 69.1 (28C, 24 x OCH2 TEG, 4 x CH2 pentaerythritol), 64.9 (4C, 4 x CH2 propargyl), 62.8
(4C, 4 x C-6), 61.3 (4C, 4 x CH2 propargyl), 50.3, 50.1 (8C, 8 x NCH2 TEG), 45.3 (1C, Cq pentaerythritol),
20.7, 20.6, 20.5 (16C, 16 x CH3 acetyl) ppm;MALDI-TOF (positive ion): m/z calcd for C117H172N24NaO56:
2832.12 [M + Na]+ Found: 2832.15.
2.2.6. Compound 7
Compound 6 (78 mg, 0.28 mmol) was deacetylated according to general method B. The crude
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 7 (44 mg,
73%) as a colourless syrup. [α]24D—2.5 (c 0.12, MeOH); Rf 0.15 (7:3 CH3CN:H2O); 1H NMR (400 MHz,
D2O) δ = 7.95, 7.89 (2 x s, 8H, 8 x CH triazole), 4.85-4.66 (m, 16H, 8 x CH2 propargyl), 4.45–4.44 (m, 16H,
4 x NCH2 TEG), 4.32 (d, J = 7.6 Hz, 4H, 4 x H-1), 3.80-3.77 (m, 20H, 4 x C-4, 8 x CH2 TEG), 3.68-3.59
(m, 8H, 4 x H-6a,b), 3.55-3.53 (m, 4H, 4 x H-5), 3.47 (dd, J = 3.3 Hz, J = 9.9 Hz, 4H, 4 x H-3), 3.43-3.37
(m, 36H, 4 x C-2, 16 x CH2 TEG), 3.30-3.27 (m, 8H, 4 x CH2 pentaerythritol) ppm; 13C NMR (100 MHz,
D2O) δ = 125.7 (8C, CH triazole), 103.1 (4C, 4 x C-1), 76.2 (4C, 4 x C-5), 73.9 (4C, 4 x C-3), 71.7 (4C,
4 x C-2), 70.7, 70.6, 70.5, 69.7 (24C, 24 x OCH2 TEG), 69.6 (4C, 4 x C-4), 69.3 (4C, 4 x CH2 pentaerythritol),
62.7 (8C, 8 x CH2 propargyl), 62.0 (4C, 4 x C-6), 51.0 (8C, 8 x NCH2 TEG), 45.8 (1C, Cq pentaerythritol)
ppm; MALDI-TOF (positive ion): m/z calcd for C85H140N24NaO40: 2159.96 [M + Na]+ Found: 2159.95.
2.2.7. Compound 9
Azide compound 8 (50 mg, 0.08 mmol) and alkyne 2 (139 mg, 0.36 mmol) were reacted in CH3CN
according to general method A. The crude product was purified by flash column chromatography (97:3
CH2Cl2:MeOH) to give compound 9 (125 mg, 89%) as a colourless syrup. [α]24D—22.9 (c 0.17, CHCl3);
Rf 0.11 (97:3 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.84, 7.76, 7.51, 7.50 (4 x s, 6H, 6 x CH
triazole), 7.40 (s, 2H, arom), 5.39 (s, 3H, 3 x skeleton protons), 5.20–4.94 (m, 24H, 6 x CH2 propargyl,
6 x CH2 ethylene glycol), 4.91-4.88 (m, 3H, 3 x skeleton protons), 4.76-4.71 (m, 3H, 3 x skeleton protons),
4.63–4.60 (m, 3H, 3 x H-1), 4.19-4.09 (m, 6H, 3 x H-6a,b), 3.98-3.97 (m, 3H, 3 x H-5), 3.90 (s, 3H, COOCH3),
2.14, 2.04, 1.99, 1.97 (4 x s, 36H, 12 x CH3 acetyl) ppm; 13C NMR (100 MHz, CDCl3) δ = 170.5, 170.3,
170.1, 170.0, 169.6 (12C, 12 x CO acetyl), 166.2 (1C, COOCH3), 151.8 (2C, 2 x Cq arom), 143.7, 141.4 (6C,
6 x Cq triazole), 124.2 (2C, 2 x Cq arom), 124.1 (6C, 6 x CH triazole), 109.1 (2C, arom), 100.4 (3C, 3 x C-1),
70.9, 70.8, 68.8, 67.1 (12C, 3 x skeleton carbons), 62.8, 62.7 (3C, 3 x C-6), 61.3 (6C, 6 x CH2 propargyl),
52.5 (1C, COOCH3), 49.6, 49.5 (6C, 6 x NCH2 ethylene glycol), 20.8, 20.7, 20.6 (12C, 12 x CH3 acetyl)
ppm; MALDI-TOF (positive ion): m/z calcd for C74H92N18NaO35: 1815.59 [M + Na]+ Found: 1815.46.
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2.2.8. Compound 10
Compound 9 (62 mg, 0.03 mmol) was deacetylated according to general method B. The crude
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 10 (42 mg,
94%) as a colourless syrup. [α]24D—8.0 (c 0.10, H2O); Rf 0.34 (7:3 CH3CN:H2O); 1H NMR (400 MHz,
D2O) δ = 7.97, 7.90, 7.83 (3 x s, 6H, 6 x CH triazole), 7.32 (s, 2H, arom), 5.13–4.73 (m, 24H, 6 x CH2
propargyl, 6 x CH2 ethylene glycol), 4.39 (d, J = 7.2 Hz, 3H, 3 x H-1), 3.91–3.90 (m, 6H, 3 x H-4,
COOCH3), 3.80-3.75 (m, 6H, 3 x H-6a,b), 3.56-3.60 (m, 6H, 3 x H-5, 3 x H-3), 3.54–3.50 (m, 3H, 3 x H-2)
ppm; 13C NMR (100 MHz, D2O) δ = 168.8 (1C, COOCH3), 152.1 (2C, 2 x Cq arom), 141.0 (6C, 6 x Cq
triazole), 126.6 (2C, 2 x Cq arom), 125.5 (6C, 6 x CH triazole), 110.1 (2C, arom), 102.8 (3C, 3 x C-1), 76.2
(3C, 3 x C-5), 73.7 (3C, 3 x C-3), 71.6 (3C, 3 x C-2), 69.5 (3C, 3 x C-4), 62.5 (6C, 6 x CH2 propargyl), 61.9
(3C, 3 x C-6), 53.8 (1C, COOCH3), 50.9, 50.7 (6C, 6 x NCH2 ethylene glycol) ppm; MALDI-TOF (positive
ion): m/z calcd for C50H68N18NaO23: 1311.46 [M + Na]+ Found: 1311.45.
2.2.9. Compound 12
Azide compound 11 (96 mg, 0.14 mmol) and alkyne 2 (315 mg, 0.82 mmol) were reacted in CH3CN
according to general method A. The crude product was purified by flash column chromatography
(95:5 CH2Cl2:MeOH) to give compound 12 (150 mg, 51%) as a colourless syrup. [α]24D—16.1 (c 0.23,
CHCl3); Rf 0.27 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.59, 7.52 (2 x s, 8H, 8 x CH
triazole), 5.41 (d, J = 2.1 Hz, 4H, 4 x H-4), 5.18 (dd, J = 8.1 Hz, J = 10.2 Hz, 4H, 4 x H-2), 5.04 (dd,
J = 3.2 Hz, J = 10.4 Hz, 4H, 4 x H-3), 4.95-4.73 (m, 24H, 12 x CH2), 4.65 (d, J = 7.9 Hz, 4H, 4 x H-1),
4.51 (s, 8H, 4 x CH2), 4.21-4.11 (m, 8H, 4 x H-6a,b), 4.01-3.97 (m, 4H, 4 x H-5), 3.37 (s, 8H, 4 x CH2
pentaerythritol), 2.14, 2.05, 1.99, 1.98 (4 x s, 48H, 16 x CH3 acetyl) ppm; 13C NMR (100 MHz, CDCl3)
δ = 170.4, 170.2, 170.0, 169.6 (16C, 16 x CO acetyl), 145.4, 144.2 (8C, 8 x Cq triazole), 124.0, 123.7 (8C,
8 x CH triazole), 100.3 (4C, 4 x C-1), 70.8, 70.7, 68.7, 67.1 (16C, 4 x skeleton carbons), 68.9 (4C, 4 x CH2
pentaerythritol), 64.6 (4C, 4 x CH2 propargyl), 62.6 (4C, 4 x C-6), 61.2 (4C, 4 x CH2 propargyl), 49.5, 49.3
(8C, 8 x NCH2 ethylene glycol), 45.1 (1C, Cq pentaerythritol), 20.8, 20.7, 20.6, 20.5 (16C, 16 x CH3 acetyl)
ppm;MALDI-TOF (positive ion): m/z calcd for C93H124N24NaO44: 2303.81 [M + Na]+ Found: 2304.49.
2.2.10. Compound 13
Compound 12 (148 mg, 0.06 mmol) was deacetylated according to general method B. The crude
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 13 (70 mg,
66%) as a colourless syrup. [α]24D + 44.8 (c 0.31, H2O); Rf 0.20 (7:3 CH3CN:H2O); 1H NMR (400 MHz,
D2O) δ = 7.94 (s, 8H, 8 x CH triazole), 4.97 (s, 16H, 8 x NCH2 ethylene glycol), 4.93–4.78 (m, 16H, 8
x CH2 propargyl), 4.44 (d, J = 7.6 Hz, 4H, 4 x H-1), 3.94 (d, J = 2.8 Hz, 4H, 4 x H-4), 3.83–3.74 (m,
8H, 4 x H-6a,b), 3.71-3.68 (m, 4H, 4 x H-5), 3.65 (dd, J = 3.0 Hz, J = 9.8 Hz, 4H, 4 x H-3), 3.57–3.53
(m, 4H, 4 x H-2), 3.34 (s, 8H, 4 x CH2 pentaerythritol) ppm; 13C NMR (100 MHz, D2O) δ = 125.4 (8C, 8 x
CH triazole), 102.9 (4C, 4 x C-1), 76.2 (4C, 4 x C-5), 73.7 (4C, 4 x C-3), 71.6 (4C, 4 x C-2), 69.6 (4C, 4 x
C-4), 69.2 (4C, 4 x CH2 pentaerythritol), 62.5 (8C, 8 x CH2 propargyl), 61.9 (4C, 4 x C-6), 50.9 (8C, 8 x
NCH2 ethylene glycol), 45.5 (1C, Cq pentaerythritol) ppm; MALDI-TOF (positive ion): m/z calcd for
C61H92N24NaO28: 1631.64 [M + Na]+ Found: 1631.59.
2.3. Lectin PA-IL Production and Purification
PA-IL in a recombinant form was produced and purified as previously described [8]. Briefly,
transformed Escherichia coli BL21(DE3) cells bearing the plasmid for PA-IL (pET25b_pa1l) were cultured
in the LB broth medium containing an appropriate antibiotic at 37 ◦C. When the culture reached an
OD600 of ≈ 0.5, protein production was induced by isopropyl 1-thio-β-d-galactopyranoside (IPTG)
added to a final concentration of 0.5 mM. Cells were incubated at 30 ◦C for 3 h, harvested by
centrifugation and resuspended in a suitable buffer. Cells were then disintegrated by sonication and the
cytosolic fraction containing soluble lectin was separated by centrifugation. PA-IL was then purified
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by affinity chromatography on a Sepharose 4B (GE Healthcare, Chicago, IL, USA) column, dialyzed
and further processed according to the previously published procedures [8]. Freeze-dried PA-IL was
stored at −20 ◦C.
2.4. Hemagglutination Inhibition Assay (HIA)
PA-IL was dissolved in the buffer with calcium ions suitable for the activity of the lectin (20 mM
Tris/HCl, 150 mM NaCl, 5 mM CaCl2, pH = 7.5) to the concentration 0.25 mg mL−1. Lectin was mixed
with carbohydrate inhibitors serially diluted in the buffer in a 5 µL:5 µL ratio. Therefore, the final
(working) concentration of the lectin was 0.125 mg mL−1. A total of 10 µL of 20% papain-treated,
azid-stabilized red blood cells B+ in the buffer was then added, and the mixture was thoroughly
mixed and incubated for 5 min at room temperature. After incubation, the mixture was again mixed,
transferred to a microscope slide, and examined. The examination was conducted using the Levenhuk
D2L NG Digital Microscope (Levenhuk, Tampa, FL, USA). Images were obtained with a Levenhuk
D2L digital camera (Levenhuk, Tampa, FL, USA) using the software ToupView for Windows (Version
3.7, Levenhuk, Tampa, FL, USA). The positive (experiment without inhibitor) and negative control
(experiment without lectin) were prepared and processed in the same way using the appropriate
volume of dissolving buffer instead of the omitted components. The minimal inhibitory concentration
(MIC) of the inhibitor able to inhibit hemagglutination was determined and compared with the
standard (d-galactose) and the potency of the inhibitor was calculated (MIC of the standard/MIC of the
inhibitor).
2.5. Surface Plasmon Resonance (SPR)
Surface plasmon resonance (SPR) experiments were performed on a BIAcore T200 instrument
(GE Healthcare, Chicago, IL, USA) at 25 ◦C, using HBST running buffer (10 mM HEPES, 150 mM NaCl,
0.5 mM CaCl2, 0.05% Tween 20, pH = 7). A CM5 sensor chip (GE Healthcare, Chicago, IL, USA) covered
with a carboxymethylated dextran matrix was used for ligand immobilization. The sensor chip surface
was activated with N-ethyl-N-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide solution
and then coated with streptavidin (Sigma-Aldrich, St. Louis, MO, USA) in 10 mM acetate pH = 5.0
according to the manufacturer’s standard protocol to a final response of 7000 RU. Unreacted groups
were blocked with 1 M ethanolamine-HCl, pH = 8.5. 0.5 mM biotinylated carbohydrate (1:1 mixture
of biotin-α-d-galactoside and biotin-β-d-galactoside for measuring channel and α-l-fucoside for
blank channel, all Lectinity, Moskow, Russia) was injected into a particular channel at a flow rate of
5 µL min−1.
In the experimental setup, SPR inhibition measurements were carried out simultaneously on both
measuring and blank channels at a flow rate of 5 µL min−1. Protein PA-IL at a concentration of 45 µM
was mixed with various concentrations of inhibitors (0.1–125 µM for studied compounds or 5–5000 µM
for d-galactose) and injected onto the sensor chip. The response of the blank channel was subtracted
from the response of lectin bound to the galactose-modified surface at equilibrium and plotted against
the concentration of inhibitor in order to determine IC50 (concentration of inhibitor resulting in 50%
inhibition of binding). As IC50 is not a constant and depends on the experimental set-up, a parameter
called potency was used for characterization. The potency of a tested inhibitor is the ratio of IC50 of a
chosen standard inhibitor (in this case, d-galactose) and the inhibitor in question. Pure lectin PA-IL
was used as a control (0% inhibition).
2.6. Isothermal Titration Microcalorimetry (ITC)
All the experiments were performed on MicroCal iTC200 (Malvern Instruments, Malvern, UK)
at 25 ◦C. The freeze-dried lectin PA-IL was dissolved in 0.1 M Tris/HCl, 500 µM CaCl2, pH = 7.5,
and equilibrated at room temperature for 1 h before ITC measurements. Multivalent galactosylated
compounds 4, 7, 10 and 13 were diluted in the same buffer and used in 0.25–0.5 mM concentrations.
Aliquots of 2 µL of the compounds were added automatically to the 0.078 mM or 0.088 mM PA-IL
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in the calorimeter cell. Blank experiments (injections of compounds to the buffer) were performed
and heat responses were subtracted. Integrated heat effects were analyzed by global fitting of
data obtained from three independent titrations for each tested compound by non-linear regression
using a single site-binding model (Microcal Origin 7, Malvern Instruments, Malvern, UK). Fitted
data yielded the association constant (Ka) and the enthalpy of binding (∆H). Other thermodynamic
parameters, i.e., changes in free energy (∆G) and entropy (∆S), were calculated from the following
equation: ∆G = ∆H − T∆S = −RT ln Ka, where T is the absolute temperature and R = 8.314 J mol−1 K−1.
The monosaccharide d-galactose was used as a control; 4 mM d-galactose was added to the 0.147 mM
PA-IL in the calorimeter cell. Two titration experiments were performed and the heat responses were
processed and evaluated as mentioned above.
2.7. Analytical Ultracentrifugation (AUC)
Analytical ultracentrifugation experiments were performed using ProteomeLab XL-I analytical
ultracentrifuge (Beckman Coulter, Indianapolis, IN, USA) equipped with an An-60 Ti rotor.
Sedimentation velocity experiments were conducted in titanium double-sector centerpiece cells
(Nanolytics Instruments, Potsdam, Germany) loaded with 390 µL of both protein sample and reference
solution (PBS buffer, pH = 7.5). PA-IL without the added ligand and PA-IL samples pre-incubated with
different concentrations of galactosylated dendrimers 4, 7, 10 and 13 and d-galactose (protein:ligand
ratios of 1:0.1, 1:1 and 1:10) were analyzed by the sedimentation velocity experiment. All the
measurements were performed in PBS buffer with 22 µM PA-IL. Data were collected using absorbance
optics at 25 ◦C at a rotor speed of 48,000 rpm. Scans were collected at 280 nm (or alternatively at 294 nm
to decrease the absorbance signal of the samples containing excess of the UV-absorbing ligands 4 and
10) at 5-min intervals and 0.003 cm spatial resolution in continuous scan mode. The partial specific
volume of the protein and the solvent density and viscosity were calculated from the amino acid
sequence and buffer composition, respectively, using the software Sednterp (http://bitcwiki.sr.unh.edu).
The data were analyzed with the continuous c(s) distribution model implemented in the program
Sedfit 15.01b [27]. For the regularization procedure, a confidence level of 0.95 was used. The plots of
c(s) distributions were created in GUSSI 1.3.1 [28].
2.8. Pseudomonas Aeruginosa Cross-Linking Assay
Pseudomonas aeruginosa CCM 3955 (ATCC 27853) cells were inoculated from stock cells stored
at −80 ◦C into a standard LB medium and were grown at 37 ◦C overnight under orbital shaking.
The bacterial culture was kept in the fridge until further use. Prior to the experiment, bacterial cells
were centrifuged at 4300× g (Eppendorf centrifuge MiniSpin, Eppendorf, Germany) for 2 min and
subsequently washed three times with PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4). Bacterial cells were then diluted in PBS to an optical density OD600 = 1.5, which
was checked using a spectrophotometer (WPA CO8000 Biovawe Cell Density Metr, Biochrom Ltd.,
Cambridge, UK). d-galactopyranoside-presenting inhibitors were diluted in ultrapure water to the
concentration of 100 mM. Bacterial cells were mixed in a 9:1 ratio with the 10x concentrated selected
compounds and gently mixed. The mixture was incubated at room temperature for 10 min and
thoroughly mixed again. An amount of 5 µL of the mixture was transferred onto a microscope slide
and observed under 100x magnification using an optical microscope (Olympus IX81F-3/IX81S1F-3,
Olympus, Tokyo, Japan). As a negative control, bacterial culture mixed with ultrapure water in 9:1
ratio was used. The images were obtained using a phase contrast method and the background of the
images was subtracted in GIMP.
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2.9. Pseudomonas Aeruginosa Adherence Assay
2.9.1. Cell Labelling
Epithelial CuFi-1 cells (an immortalized epithelial cell line derived from cystic fibrosis human
lungs, ATCC, Kielpin, Poland) were labelled with PKH67 (Fluorescent Cell Linker Kit, Sigma-Aldrich,
St. Louis, MO, USA), a green fluorescent membrane marker, as follows. An aliquot of cell suspension
containing 7 × 106 cells was washed with PBS buffer and centrifuged (100× g for 5 min). The cell pellet
was resuspended in 250 µL of Diluent C (Fluorescent Cell Linker Kit, Sigma-Aldrich, St. Louis, MO,
USA). Immediately, an equal volume of 8 µM PKH67 in Diluent C (2 µL of PKH67 in 248 µL of Diluent
C) was added to the cell suspension. After 5 min incubation at room temperature with periodic mixing,
the staining reaction was stopped by adding an equal volume of 1% Fetal Bovine Serum (FBS, GibcoTM
Invitrogen, Paisley, UK) in PBS. After 1 min incubation with FBS, the suspension was centrifuged
(100× g for 10 min). Finally, the cells were washed three times with Bronchial Epithelial Cell Growth
Basal Medium (Lonza, Basel, Switzerland), followed by centrifugation (100× g for 5 min).
Pseudomonas aeruginosa strain 1763 (University Hospital Motol, Prague, Czech Republic) was
stained with PKH26 (Fluorescent Cell Linker Kit, Sigma-Aldrich, St. Louis, MO, USA), a red fluorescent
membrane marker. Bacteria were grown in a suspension culture in PS medium (peptone/casein digest)
in an Erlenmeyer flask for 14 h. The culture was washed with PBS buffer and centrifuged (13,400× g for
5 min). The pellet containing 1.5 × 109 bacteria was resuspended in 125 µL of Diluent C (Fluorescent
Cell Linker Kit, Sigma-Aldrich, St. Louis, MO, USA) and an equal volume of 16 µM PKH26 in Diluent
C (2 µL of PKH26 in 123 µL of Diluent C) was added to the bacterial suspension. The bacteria/dye
suspension was incubated for 30 min at room temperature with periodic mixing. The staining was
quenched by adding an equal volume of 1% BSA (Bovine Serum Albumin, Merck, Kenilworth, NJ,
USA) in PBS. The suspension was incubated with BSA for 1 min to allow the binding of excess dye
and then centrifuged (15,700× g for 10 min). Bacteria were washed two times with PBS, followed by
centrifugation (13,400× g for 7.5 and 5 min).
2.9.2. Inhibition of Pseudomonas Aeruginosa Adhesion to Epithelial Cells
Epithelial cells CuFi-1 stained with PKH67 were seeded at 8.4 × 104 cells/well onto 96-well plates
(CellBIND® 96-well Flat Clear Bottom Black Polystyrene Microplates, Corning Incorporated, Corning,
NY, USA) and incubated for 42–45 h at 37 ◦C, 5% CO2 to form a confluent monolayer and regenerate.
Prior to the assay, wells were washed with PBS. Compounds 4, 7, 10 and 13 were serially diluted
with PBS to the desired concentrations. PKH26-stained bacteria P. aeruginosa were added to the
diluted inhibitor solutions. Bacterial suspensions were immediately added to the wells (50 µL/well).
The input ratio was about 100 bacteria per epithelial cell (8.4 × 106 bacteria/well). A suspension
without any inhibitor was used as a control. After 2 h incubation at room temperature, the wells were
extensively washed three times with PBS to remove non-adhered bacteria. The fluorescence of adhered
P. aeruginosa cells (Ex 522 nm, Em 569 nm for PKH26) on epithelial cells (Ex 470 nm, Em 505 for PKH67)
was quantified using the spectrofluorometer Tecan Infinite M200 Pro (Tecan Group Ltd., Männedorf,
Switzerland). Results were expressed as a relative fluorescence ratio of P. aeruginosa/CuFi-1. Three
independent incubations were performed.
The effect of compounds 10 and 13 in combination with previously published tetravalent
α-l-fucose-presenting glycocluster (compound 14, see Figure 1) [29] was also determined. Compounds
10 and 13, respectively, were serially diluted and mixed with compound 14 in a constant concentration
of 0.25 mM. PKH26-stained bacteria P. aeruginosa were added to the inhibitors solutions and experiments
were performed and evaluated as mentioned above. In addition to control (suspension without any
inhibitor), the bacterial suspension with only 0.25 mM compound 14 was also processed and evaluated.
Data were analyzed in GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA).
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3.1. Synthesis of Multivalent Galactosides
Similarly to our recent studies [25,30,31], metyl gallate equipped with azide-containing
tetraethylene glycol 1 and ethylene glycol chains 8 and pentaerythritol cores 5 and 11 [25]
were chosen as multivalent scaffolds (Scheme 1). We efficiently prepared peracetylated propargyl
β-d-galactopyranoside 2 by known method [32]. The galactoclusters were built from the above structural
elements by applying 1,3-dipolar azide-alkyne cycloaddition click reactions. First, the trivalent
cores 1 and 8 were coupled with propargyl 2,3,4,6-tetra-O-acetyl-β-d-galactopyranoside 2 via
the Cu(I)-catalyzed azide-alkyne cycloaddition click reaction (CuAAC) to get protected trivalent
galactosides 3 and 9, in good yields. Similarly, tetravalent scaffolds 5 and 11 were coupled by CuAAC
reaction with galactoside 2 to produce the protected galactoclusters 6 and 12, respectively. The final
products were obtained by Zemplén-deacetylation of 3, 6, 9 and 12, to result in compounds 4, 7, 10 and
13, respectively, showing differences in the valency, flexibility and spatial arrangement of galactosides.
Compounds were tested as potential ligands of tetrameric, galactose-specific lectin PA-IL.
3.2. Inhibition of PA-IL with Multivalent Galactosylated Compounds
The preliminary investigations of the interactions of the multivalent galactosylated compounds
with PA-IL were performed using hemagglutination inhibition assay with microscope detection.
The minimal inhibitory concentrations (MICs) of compounds able to completely inhibit
hemagglutination caused by lectin PA-IL were determined and the potencies of the inhibitors were
calculated by comparison with the standard (d-galactose). All compounds were able to inhibit
hemagglutination significantly better than simple d-galactose (see Table 1 and Figure 2) with compound
7 being the best inhibitor—256 times better than d-galactose. The least efficient inhibitor was compound
10 (with potency value of 64), whereas compounds 4 and 13 were in between (128). Taking into
account the simple effect of the increased concentration of galactose units in the multivalent compound
(parameter β, potency/valency), compound 7 (the tetravalent compound with longer linkers, β = 64)
is still the best inhibitor and compound 10 (trivalent with shorter ethylene-linker, β = 21.3) the
least efficient. Considering compounds 4 and 13, differences in inhibitory efficiency were observed.
Compound 4 (trivalent, tetraethylene glycol-linker, β = 42.7) was better than compound 13 (tetravalent,
ethylene-linker, β = 32). Generally, a more efficient inhibitory activity was associated with tetravalent
compounds and longer linkers.
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Table 1. The MIC (minimal inhibitory concentration) values and potencies of tested inhibitors obtained
for the inhibition of hemagglutination caused by lectin PA-IL.
Inhibitor MIC Potency 2 Valency β 3
d-galactose 1 6.25 mM 1 1 1
Compound 4 48.83 µM 128 3 42.7
Compound 7 24.41 µM 256 4 64
Compound 10 97.66 µM 64 3 21.3
Compound 13 48.83 µM 128 4 32
1 Standard, 2 MIC of standard/MIC of inhibitor, 3 Potency/Valency.
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The surface plasmon resonance (SPR) technique was employed to further analyse the competitive
inhibition of PA-IL binding to a multivalent chip surface. Sensor chip presenting d-galactopyranoside
residues was treated by a constant concentration of PA-IL, and the concentrations of the tested inhibitors
were gradually decreased to determine IC50. All the tested compounds clearly demonstrated a higher
inhibition potency when compared to d-galactose (see Table 2). The most potent inhibitor appeared
to be compound 13, with a more than 40 times higher inhibition potency than d-galactose (more
than 10 times when calculating parameter β considering the effect per monomer unit) followed by
compounds 4, 10 and 7, that displayed almost identical inhibitory effects (see Figure 3).
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Table 2. The IC50 (concentration of inhibitor resulting in 50% inhibition of binding) values and potencies
of the tested inhibitors obtained by SPR for lectin PA-IL.
Inhibitor IC50 Potency 2 Valency β 3
d-galactose 1 187.1 µM 1 1 1
Compound 4 6.8 µM 27.5 3 9.2
Compound 7 7.3 µM 25.6 4 6.4
Compound 10 7.4 µM 25.3 3 8.4
Compound 13 4.3 µM 43.5 4 10.9
1 Standard, 2 IC50 of standard/IC50 of inhibitor, 3 Potency/Valency.
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3.3. Thermodynamics of the Interactions
The interactions of PA-IL with d-galactopyranoside-presenting glycoclusters were directly
characterized by isothermal titration calorimetry. All the compounds were able to bind to PA-IL with
an affinity three orders of magnitude higher than simple d-galactose (see Table 3). Interactions were
exothermic- and enthalpy-driven, with significantly unfavourable entropy. Interactions with tetravalent
compounds displayed higher unfavourable entropy values than those with trivalent compounds,
probably corresponding to the larger loss of flexibility during binding. However, the entropy
loss was connected with increased favourable enthalpy values in an example of enthalpy-entropy
compensation [33]. The best binding partner for lectin PA-IL, according to the obtained affinity
constants, was compound 13, followed by compound 7, i.e., the tetravalent variants. The stoichiometry
(n value) of interactions was lower than 1, suggesting that one molecule of inhibitor is recognized by
several binding sites of lectin PA-IL. No aggregation was observed during or after the calorimetry
experiments, implying that the binding is either intramolecular (within the same PA-IL tetramer) or the
particles resulting from intermolecular binding are too small to form visually observable aggregates.
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Table 3. Thermodynamic parameters of the interactions between lectin PA-IL and the tested inhibitors.
Inhibitor Valency n Ka [104 M−1]
d-galactose 1 0.78 ± 0.05 0.68 ± 0.038
Compound 4 3 0.51 ± 0.01 128 ± 15.1
Compound 7 4 0.32 ± 0.01 281 ± 23.5
Compound 10 3 0.53 ± 0.01 122 ± 12.8
Compound 13 4 0.21 ± 0.01 470 ± 54.5
Inhibitor ∆H [kJ/mol] −T∆S [kJ/mol] ∆G [kJ/mol]
d-galactose −37.8 ± 2.92 15.9 ± 2.12 −21.9 ± 1.23
Compound 4 −80.7 ± 1.01 45.9 ± 5.99 −34.8 ± 4.11
Compound 7 −110.0 ± 0.82 72.7 ± 6.65 −36.8 ± 3.09
Compound 10 −68.2 ± 0.75 33.4 ± 3.87 −34.7 ± 3.64
Compound 13 −134.0 ± 1.45 95.7 ± 12.15 −38.1 ± 4.42
3.4. Cross-linking of Lectin PA-IL with Multivalent Galactosylated Inhibitors
The sedimentation velocity experiment was used to investigate the cross-linking properties of the
galactosylated dendrimers (compounds 4, 7, 10 and 13) on the lectin PA-IL. In the absence of dendrimers,
PA-IL was mostly present as a tetramer with the sedimentation coefficient of 4.2 S (estimated molar
mass of 48.4 kDa), about 5% of PA-IL had an s-value of 6.4 S and corresponded most likely to an
octameric species. The addition of dendrimers 7, 10 and 13 (but not 4) induced the formation of the
6.4 S particle (see Figure 4). At a 1:0.1 protein to ligand ratio, the highest level of cross-linking was
observed for compound 7 (~30%), followed by compounds 10 and 13 (~15%). In the molar excess of the
ligand, the percentage of 6.4 S species decreased and was comparable to the sample without the ligand
added. The ligands (if absorbing in UV) had a sedimentation coefficient between 0.3 and 0.5 S. Since
the formation of larger oligomers or precipitation were not detected by analytical ultracentrifugation,
the data suggests that dendrimers 7, 10 and 13 cross-link PA-IL in a well defined way (formation of
octamers). In the control experiment, d-galactose had a negligible effect on the percentage of the 6.4 S
particle (see Figure S1). According to the results, trivalent compound 4 did not form intermolecular
cross-links in the used set-up, probably due to the combination of the topology of its branches and
the length of its linkers. Compared with the trivalent compound 10, which forms intermolecular
cross-links, the longer linkers of compound 4 are probably more suitable for intramolecular binding to
several binding sites of PA-IL. In the molar excess of all the compounds, the binding sites of PA-IL
seemingly bind separate molecules of dendrimers, which prevents cross-linking.
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3.5. Cross-linking of Pseudomonas Aeruginosa Cells with Multivalent Galactosylated Inhibitors
The abilities of d-galactopyranoside-presenting inhibitors to cross-link whole Pseudomonas
aeruginosa cells via interactions with lectin PA-IL on the surface were investigated by cell cross-linking
assay with microscope detection. The cell aggregates clearly distinguishable from the negative
control were only observed in low quantities and mainly in highly used concentrations of the tested
compounds (2.5–5 mM, see Figure 5). The cell cross-linking activity of the tested compounds was
either generally weak or the resulting cell aggregates were too small to be detected by the used
methodology in the current set-up. Considering compound 13, no aggregates were observed, even
in 5 mM concentration. On the other hand, compound 7 displayed the highest cross-linking activity
and aggregates distinguishable from the negative control were observed even in a concentration of
1.25 mM (see Figure S2).
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Figure 5. Cross-linking of Pseudomonas aeruginosa cells with d-galactopyranoside-presenting inhibitors.
The P. aeruginosa cells with no added inhibitors were used as a control. Magnification 100x, phase
contrast, background subtraction in GIMP, triplicates. The results for the highest concentrations used
are presented. For the other concentrations used, see Figures S2 and S3 in the Supplementary data.
The representative aggregates are highlighted by the black arrows. (a) Results for compounds 4 and 10;
(b) Results for compounds 7 and 13.
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3.6. Inhibition of Pseudomonas Aeruginosa Adhesion to Epithelial Bronchial Cells
Ex vivo bacterial adherence assay was used for the evaluation of the ability of tested compounds
to inhibit the adhesion of P. aeruginosa (ST 1763, isolated from a CF patient) to epithelial bronchial cells
(CuFi-1, derived from a CF patient). Bacteria labeled with PKH26 were incubated with PKH67-labeled
CuFi-1 in the presence of compounds 4, 7, 10 and 13 or PBS as untreated control (see Figure 6).
Compounds 4 and 7 displayed no inhibitory effect on bacterial adhesion compared to the control.
On the contrary, compounds 10 and 13 had a significant protecting effect in concentrations ≥1 mM.
In the highest concentration (2 mM), compounds 10 and 13 were able to reduce bacterial adhesion to
approximately 32% and 42%, respectively, compared to the untreated control. However, the addition of
compounds 10 and 13 in some lower concentrations (≤125 µM) resulted in a statistically significantly
increased fluorescent signal (see Figure 6c,d). Furthermore, the combined effect of anti-PA-IL inhibitors
(compounds 10 and 13) and the previously published PA-IIL inhibitor (compound 14) was tested (see
Figure 7). PA-IIL (LecB) is another lectin from Pseudomonas aeruginosa involved in pathogenicity [8].
According to the previous study, compound 14 was used in its most effective concentration (250µM) [29]
and combined with the concentration gradient of compound 10 or 13. The mixtures of compounds
10 or 13 in the highest concentration (2 mM) with compound 14 (250 µM) reduced the P. aeruginosa
adhesion to approximately 22% and 23%, respectively. Considering these combined experiments, no
response exceeding the untreated control was observed for any used concentration of compounds 10
and 13.
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Figure 6. Adherenc of P. aeruginosa to human bronchial epitheli l ll Fi-1) in the presence of the
tested compounds. Monolayers f PKH67-labeled CuFi-1 cells were incubated for 2 h with suspensions
containing PKH26-l beled P. aeruginosa and tested compoun s (grey bars) or PBS as a control (black
bars). After discarding of non-adhered bacteria, the relative fluorescence of adhered P. aeruginosa and
CuFi-1 was quantified using Tecan Infinite M200 Pro. Results are expressed as a relative fluorescence
ratio of P. aeruginosa/CuFi-1 plotted as a function of compounds concentrations. Plotted data are
means ± SD of three independent incubations. * indicates significant difference (p < 0.05; Dunnett test).
(a) Results for compound 4; (b) Results for compound 7; (c) Results for compound 10; (d) Results for
compound 13.
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Monolayers of PKH67-labeled CuFi-1 cel s bated for 2 h with uspensions containing
PKH26-labeled P. aeruginosa and 250 µM compou 14 c bined with compound 10 or 13 (dark grey
bars) or only 250 µM compound 14 (light grey bar). Suspension with PKH26-labeled P. aeruginosa in
PBS was used as an untreated control (black bar). After discarding non-adhered bacteria, the relative
fluorescence of adhered P. aeruginosa and CuFi-1 was quantified using Tecan Infinite M200 Pro. Results
are expressed as a relative fluorescence ratio of P. aeruginosa/CuFi-1 plotted as a function of anti-PA-IL
compounds concentration. Plotted data are means ± SD of three independent incubations. * indicates
significant difference from untreated control (p < 0.05; Dunnett test). # indicates significant difference
from experiment using only 250 µM compound 14 (p < 0.05; Dunnett test). (a) Results for compound
10; (b) Results for compound 13.
4. Discussion
An expeditious click-chemistry approach was applied to synthesize tri- and tetravalent
glycodendri er of different flexibili ies bearing the β-d-galactoside units with ifferent spatial
arran ements. The ability of th synthetized β-d-galactopyranoside-containing tri- and t travalent
glycoclusters to inhibit the lectin PA-IL (LecA) from Pseudomonas aeruginosa was determined by
hemagglutination inhibition assay (HIA) with microscope detection and by SPR inhibition assay using
immobilized d-galactopyranoside. Hemagglutination inhibition assay is a quick and robust method
commonly used for characterization of lectin-carbohydrate interactions [34]. The carbohydrate-covered
surface of red blood cells enables lectins to employ their multivalency and potential inhibitors could be
suitably tested for their ability to compete with this native surface. On the other hand, he agglutination
assay relies fully on visual detection and thorough com arisons with positives and negativ s controls.
SPR inh bition assay i flow-through arrangement with carbohydrat s mmobilized on the static
sensor chip could theoretically better mimic the real environment of lectin’s action—binding to lung
tissues. However, SPR is sensitive to aggregation and potential artifacts caused by cross-linking of
lectins [30]. By combination of these two diverse methods, their weaknesses could be compensated
and the inhibitory activity of tested compounds verified. According to the hemagglutination assay,
tetravalent compound 7 was the best inhibitor (potency 256, β = 64). However, the trivalent compound
4 (potency 128, β = 42.7) was the second best compound, suggesting a preference for compounds with
longer and more flexible tetraethylene glycol-linker over shorter ethylene-linker, regardless of their
valency. Considering SPR as ay, compound 13 was determined to be the best i hibitor. In contrast to
hemagglutination assay, there was no cl ar correlation observed between the compounds’ valency
or structure and their i hibitory effect. This demonstrates not only the importance of structural
arrangement of the studied compounds but also of the nature of the tested surface. As SPR and HIA
have completely different set-ups and detection principles, the acquisition of different data was not
surprising. The fact that diverse techniques for determination of inhibitory potency provide different
and sometimes even contradictory results is well known [11,35] and hinders the reliable in vitro
evaluation of inhibitors. Nevertheless, both methods confirmed that all the tested compounds could
inhibit PA-IL significantly better than simple d-galactose.
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The interactions of β-d-galactopyranoside-containing compounds and PA-IL were also
characterized by isothermal titration microcalorimetry to obtain true binding affinities and
thermodynamic parameters. Interactions were enthalpy-driven with strong unfavorable entropy.
As carbohydrates are very flexible molecules, a strong entropy barrier is usually observed during
binding, i.e., fixation of carbohydrates into the binding sites [36]. Binding affinities were three orders
of magnitude higher than for d-galactose. The affinities obtained by ITC are not equal to inhibitory
activities but could correlate with them. The best ligand for the lectin PA-IL in the ITC set-up (in solution
method) was compound 13, followed by compound 7, i.e., the tetravalent ligands. Although the entropy
loss was significantly higher during interactions with tetravalent compounds than with trivalent,
the enthalpy compensation resulted in higher affinities to tetravalent variants. The combination of
inhibition assays and direct affinity measurement confirms that the tested compounds are suitable
ligands/inhibitors of lectin PA-IL but the variation of the results (see Figure 8) obtained by different
methods thwarted the straightforward selection of compounds with the highest potential to affect
Pseudomonas aeruginosa in vivo.
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Figure 8. Comparison of effectiveness of tested compounds obtained by hemagglutination inhibition
assay (HIA), SPR inhibition assay (SPR) and isothermal titration microcalorimetry (ITC). Values for
parameters β (HIA and SPR) and Ka (ITC) were relativized to the best inhibitor/ligand (100%) obtained
by each method and compared.
The PA-IL-cross-linking ability of carbohydrate-based inhibitors was associated with their potential
to inhibit Pseudomonas aeruginosa biofilm formation [23]. Moreover, to determine the possible correlation
between cross-linking and anti-adhesion properties, analytical ultracentrifugation with lectin PA-IL
and cross-linking assay with whole P. aeruginosa cells were employed. Considering AUC, compounds
7, 10 and 13 cross-linked PA-IL in well defined manner, forming octamers. The formation of octamers
decreased in the molar excess of tested compounds, suggesting saturation of binding sites of PA-IL.
Compound 7 was the best cross-linker; on the other hand, no cross-linking activity was observed for
compound 4. The cross-linking assay with whole cells was further used to better mimic the in vivo
condition. Formation of aggregates was observed for compounds 7, 10 and, in contrast to AUC,
also for compound 4. On the other hand, no clearly distinguishable aggregates were detected when
using compound 13. Generally, the number of aggregates was low, suggesting a low cross-linking
activity in the used set-up or the formation of aggregates too small to be reliably detected by the
utilized methodology.
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The contradictory results from inhibition/affinity assays and cross-linking assays demonstrates
the problems with the in vitro evaluation of potential inhibitors. Since the in vivo testing (especially
for potential human drugs) is beyond the possibility of basic research, the ex vivo bacterial adherence
assay was chosen as the closest possible to the real system. This assay was used to monitor the effect of
the tested compounds on bacteria–cell interaction, utilizing the epithelial cells and P. aeruginosa strain
derived from a cystic fibrosis (CF) patient and direct detection of adhered bacteria by fluorescence.
Although compounds 4 and 7 performed well in in vitro tests, they have essentially no visible
protective effect in the adhesion assay. On the other hand, compounds 10 and 13 displayed significant
anti-adhesion effect in concentrations ≥1 mM and could be suitable for prophylaxis against the
bacterial colonization of bronchial cells. However, the efficient concentrations were rather high,
which could be difficult to achieve in vivo and could increase the possibility of negative side effects.
Furthermore, the increase of fluorescence signal (i.e., the number of adhered bacterial cells) was
observed in lower concentrations (≤125 µM) of compounds. This could have been caused by the
cross-linking of PA-IL on the surface of the bacterial cells and corresponds to the results from AUC
assay. Alternatively, some galactose-binding protein on the surface of epithelial cells could additionally
interact with β-d-galactopyranoside-containing compounds, linking bacteria and epithelial cells
together. The insufficient maintenance of effective concentration in the lungs of CF patients could
theoretically lead to an increased adhesion of P. aeruginosa to the tissues. Combined with the fact that
compound 7 (the best cross-linker) failed in the adherence assay, the cross-linking ability cannot be
associated with anti-adhesion properties.
In addition to PA-IL, Pseudomonas aeruginosa also produces a fucose-specific lectin PA-IIL (LecB),
which is involved in the adhesion and in the biofilm formation [37] and was shown to block ciliary
beating of epithelial cells [8]. As PA-IIL has a completely different carbohydrate specificity than PA-IL,
the β-d-galactopyranoside-containing compounds cannot inhibit this lectin and combination of specific
inhibitors is necessary for maximal inhibition of adhesion. Therefore, the combined effect of compounds
10 or 13, respectively, and previously prepared tetravalent α-l-fucose-presenting glycocluster 14 [29]
was evaluated. The most effective combinations of inhibitors (2 mM compound 10 or 13 plus 250 µM
compound 14) were able to reduce bacterial adhesion to approximately 22% and 23%, respectively.
The increase of fluorescent signal in lower concentrations of compounds 10 and 13 (compared to
the experiment using only 250 µM compound 14), was observed in these combined experiments,
too. However, it did not exceed the value of untreated negative control. Therefore, we suggest the
use of a combination of galactose/fucose-containing inhibitors for prophylaxis purposes to achieve
maximal anti-adhesion activity and the elimination of possible negative effects caused by using only
galactose-based inhibitors. Considering CF patients, the problem of highly effective concentrations of
tested compounds could be overcome by the fact that it is feasible to reach high doses of medication
applied directly to lungs via inhalation [38,39].
5. Conclusions
β-d-galactopyranoside-containing tri- and tetravalent glycoclusters, synthesized by
click-chemistry, were tested by a variety of methods to determine their inhibitory effect against the lectin
PA-IL from Pseudomonas aeruginosa. All the compounds were found to be suitable inhibitors/ligands
of the lectin in vitro, with a significantly better inhibitory effect/affinity than simple d-galactose.
Compounds 10 and 13 were also able to decrease adhesion of P. aeruginosa cells to bronchial human
cells in the ex vivo adhesion assay. In contrast to inhibition of biofilm formation [23], the cross-linking
ability of multivalent inhibitors could not be directly associated with the anti-adhesion potential.
The best results in adhesion assay were obtained for compounds 10 and 13 in combination with
previously investigated tetravalent α-l-fucose-containing inhibitor of lectin PA-IIL, another virulence
factor of P. aeruginosa. Therefore, future research will be focused on the simultaneous inhibition of both
lectins, possibly by using mixed fucose/galactose-based inhibitors. In conclusion, tri- and a tetravalent
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compounds 10 and 13 are promising candidates for testing using a mouse cystic fibrosis model [40]
with potential future utilization as prophylactic agents against bacterial colonization of lungs.
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